Frequent outbreaks of coronaviruses underscore the need for antivirals and vaccines that
can counter a broad range of coronavirus types. We isolated a human antibody named 76E1 …

The coronavirus disease 2019 (COVID-19) pandemic has created a worldwide crisis and
inspired an urgent search for prevention and treatment of severe acute respiratory syndrome …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Abstract The Ad26. COV2. S vaccine,–has demonstrated clinical efficacy against
symptomatic COVID-19, including against the B. 1.351 variant that is partially resistant to …

Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier
and caused widespread disease in the past two decades. The development of a universal …

Understanding the mechanism for antibody neutralization of SARS-CoV-2 is critical for the
development of effective therapeutics and vaccines. We recently isolated a large number of …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …